You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

CLINICAL TRIALS PROFILE FOR IMATINIB MESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Imatinib Mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Medical Research Council Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed National Cancer Institute (NCI) Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Eastern Cooperative Oncology Group Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00004932 ↗ STI571 in Treating Patients With Recurrent Leukemia Completed National Cancer Institute (NCI) Phase 1 2002-01-01 RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imatinib Mesylate

Condition Name

Condition Name for Imatinib Mesylate
Intervention Trials
Leukemia 58
Gastrointestinal Stromal Tumor 23
Chronic Myeloid Leukemia 18
Gastrointestinal Stromal Tumors 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Imatinib Mesylate
Intervention Trials
Leukemia 137
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 105
Leukemia, Myeloid 101
Gastrointestinal Stromal Tumors 54
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imatinib Mesylate

Trials by Country

Trials by Country for Imatinib Mesylate
Location Trials
United States 962
Canada 73
Australia 53
Italy 48
United Kingdom 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Imatinib Mesylate
Location Trials
Texas 82
California 66
New York 55
Pennsylvania 46
Massachusetts 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imatinib Mesylate

Clinical Trial Phase

Clinical Trial Phase for Imatinib Mesylate
Clinical Trial Phase Trials
Phase 4 9
Phase 3 34
Phase 2/Phase 3 5
[disabled in preview] 211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Imatinib Mesylate
Clinical Trial Phase Trials
Completed 235
Terminated 58
Unknown status 25
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imatinib Mesylate

Sponsor Name

Sponsor Name for Imatinib Mesylate
Sponsor Trials
National Cancer Institute (NCI) 111
Novartis Pharmaceuticals 52
Novartis 44
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Imatinib Mesylate
Sponsor Trials
Other 340
Industry 174
NIH 116
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.